You are here

Article Text

Article menu
Download PDFPDF
DTB select
Cytisinicline for vaping cessation

https://doi.org/10.1136/dtb.2025.000006

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key learning points

    • A small, short-term, placebo-controlled trial evaluated whether cytisinicline (cytisine) plus behavioural support was more effective than behavioural support alone for vaping cessation.

    • A 12-week course of cytisinicline resulted in more people achieving short-term continuous abstinence from e-cigarettes than placebo (31.8% vs 15.1%).

    • The study did not include the important outcome measure of continued abstinence from e-cigarettes at 1 year.

    A small double-blind randomised controlled trial found that cytisinicline (cytisine) in addition to behavioural support increased the proportion of people who achieved continuous abstinence from e-cigarettes compared with placebo plus behavioural support (31.8% vs 15.1%) during the final 4 weeks of a 12 week treatment course.1

    Overview

    This study was conducted at five US sites and recruited 160 adults (mean age 34 years; 85% ‘white’, 9% ‘black or African American’) who reported current daily use of a nicotine-containing e-cigarette, had a positive saliva cotinine test and …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.